Skin Care
Ruxolitinib is a selective Janus-activated tyrosine kinases inhibitor (JAK1 and JAK2), available in oral (Jakafi™) and topical (Opzelura™) formulations. It is used to treat myelofibrosis, graft-versus-host disease, and in dermatology, atopic dermatitis, and non-segmental vitiligo.
Send Message